CYP450 checker
(CYP3A4, 2C9, 2C19, 2D6, 1A2, 2A6, 2B6, P-gp)
CYP3A4
CYP3A4 Inhibitor
-
CYP3A4 Inducer
-
CYP3A4 substrate
-
CYP2C9
CYP2C9 Inhibitor
-
CYP2C9 Inducer
-
CYP2C9 substrate
-
CYP2C19
CYP2C19 Inhibitor
-
CYP2C19 Inducer
-
CYP2C19 substrate
-
CYP2D6
CYP2D6 Inhibitor
-
CYP2D6 Inducer
-
CYP2D6 substrate
-
CYP1A2
CYP1A2 Inhibitor
-
CYP1A2 Inducer
-
CYP1A2 substrate
-
CYP2A6
CYP2A6 Inhibitor
-
CYP2A6 Inducer
-
CYP2A6 substrate
-
CYP2B6
CYP2B6 Inhibitor
-
CYP2B6 Inducer
-
CYP2B6 substrate
-
P-Glycoprotein
P-GP Inhibitor
-
P-GP Inducer
-
P-GP substrate
-
References
Hladun O, Papaseit Fontanet E, Martín S, Barriocanal A, Poyatos L, Farré M, et al. Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse. Pharmaceutics. 2021 Sep 22;13:1532.
Patel K, Bhatt M, Hirani R, Patel V, Shah G, Chorawala M. Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon. 2022 Oct 1;8:e11278.
Kwon S, Judson M. Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications. Journal of Clinical Medicine. 2024 Feb 22;13:1250.
Alreja G, Inayatullah S, Goel S, Braden G. 14 Rhabdomyolysis Caused by Unusual Interaction Between Simvastatin and Azithromycin. Journal of cardiovascular disease research. 2012 Oct 1;3:319–22.
Lo C, Nguyen S, Yang C, Witt L, Wen A, Liao T, et al. Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. Clinical and Translational Science. 2020 Apr 13;13.
Rettie A, Jones J. Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annual review of pharmacology and toxicology. 2005 Feb 1;45:477–94.
Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C. CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmacogenomics and Personalized Medicine. 2016 Dec 1;9:131–47.
.